Delcath Systems DCTH
NASDAQ DCTH
$21.77 +1.67 (+8.31%)
At close: Nov 11, 2026 · 4:00 PM EST

Delcath Systems (DCTH) Gains from Sales and Divestitures (2010 - 2017)

Updated

Delcath Systems' Gains from Sales and Divestitures came in at $2,000 for Q4 2017.

Analysis

Delcath Systems (DCTH) Gains from Sales and Divestitures (2010 - 2017) Analysis & Trends

For FY2017, Delcath Systems' Gains from Sales and Divestitures was -$18,000.

  • Going back by year, Gains from Sales and Divestitures was -$1,000 in FY2016, -$15,000 in FY2015, -$282,000 in FY2014 and -$5,000 in FY2013.
  • The Q4 2017 figure represents the highest quarterly Gains from Sales and Divestitures in data going back to Q3 2010.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Thermo Fisher Scientific 266.22 Bn 242.86 Bn 5.13 Bn
2 Abbott Laboratories 191.31 Bn 165.77 Bn 7.39 Bn
3 Danaher 166.16 Bn 145.82 Bn 3.84 Bn
4 Intuitive Surgical 155.98 Bn 136.40 Bn 2.08 Bn
5 Medtronic 130.05 Bn 96.18 Bn 6.34 Bn
6 Stryker 123.40 Bn 109.59 Bn 4.25 Bn
7 Boston Scientific 64.81 Bn 60.48 Bn 3.43 Bn
8 Edwards Lifesciences 59.87 Bn 43.18 Bn 1.35 Bn
9 Medline 53.84 Bn 50.96 Bn 1.93 Bn
10 Delcath Systems 698.90 Mn 318.29 Mn 31.18 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2017 2,000.00
Mar 31, 2017 -20,000.00
Jun 30, 2016 -1,000.00
Dec 31, 2015 -13,000.00
Dec 31, 2014 -135,000.00
Sep 30, 2014 -24,000.00
Jun 30, 2014 -41,000.00
Mar 31, 2014 -82,000.00
Sep 30, 2013 -10,000.00
Jun 30, 2013 5,000.00
Jun 30, 2012 -52,000.00
Mar 31, 2012 52,000.00
Dec 31, 2010 13,730.00
Sep 30, 2010 -13,460.00
API Access

Delcath Systems Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=DCTH&period=max&api_key=YOUR_API_KEY